Kadans Science Partner and Canary Wharf Group (CWG), London, are developing an innovation facility providing access to fully fitted laboratories and space for developing life science companies, following the announcement of a joint venture to establish a new UK Life Sciences cluster at Canary Wharf. DDW’s Megan Thomas caught up… Read More
This is the latest episode of the free narrated DDW podcast, “CROs and targeted protein degradation offer an exciting future”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “CROs: Drug discovery expertise on hand” and “Why the emergence… Read More
This is the latest episode of the free DDW podcast, “CROs and targeted protein degradation offer an exciting future”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “CROs: Drug discovery expertise on hand” and “Why the emergence of… Read More
Vésale Bioscience, a company in the research and development of solutions and treatments using phage therapy for multi-resistant infections, has received €1.8 million in grants from the European Innovation Council (EIC) Accelerator Fund for its PhageDiag project. The project is a phagogram using artificial intelligence (AI) that… Read More
DDW has published the first of its new Guide Series, Where is the global innovation and the opportunity in cell and gene therapy? It is sponsored by Astrea BioSeparations and Benchling. In this free, exclusive guide, you will learn more about: The successes… Read More
Moderna has become the newest member of the UK’s pharmaceutical industry body, the Association of the British Pharmaceutical Industry (ABPI), building on the long-term commitment by the American-based company to expand its footprint and investment in the UK. Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics… Read More
Over the three days of Advanced Therapies Week (ATW) 2023 in Miami, Florida, US, from 18 to 20 January, DDW’s Megan Thomas heard from attendees about what they were most looking forward to learning from the event, as well as why they think the potential of cell and gene therapies… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Clinical trials have led our news section this week, with positive results… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Clinical trials have led our news section this week, with positive results… Read More
Gut bacteria can influence brain health, according to a study of mice genetically predisposed to develop Alzheimer’s-like brain damage. The findings suggest a new approach to treating Alzheimer’s and other neurodegenerative diseases. Context Researchers at Washington University School of Medicine in St Louis showed that… Read More
Dr Julie Warner is Vice President of Regulatory Affairs at global drug development consultancy, Boyds. In this article, she provides her expert insights into the key regulatory developments likely to shape the global drug development industry this year. Implementation of the EU Clinical Trials Regulation The way clinical trials (CTs)… Read More
This is the latest episode of the free DDW podcast, “A deep dive into the future of ophthalmology”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Innovation, investment and commitment: Genentech’s approach to the future of ophthalmology” and “… Read More
This is the latest episode of the free DDW podcast, “A deep dive into the future of ophthalmology”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Innovation, investment and commitment: Genentech’s approach to the future of ophthalmology” and “… Read More
Integrated DNA Technologies has purchased next generation sequencing (NGS) research assays from Invitae Corporation under the trademarked name Archer. The integration of IDT’s portfolio with the acquired NGS research assays—which have been foundational in researching novel cancer fusions—will empower labs with a solution to uncover biomarkers and… Read More
Boston-based Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has launched Bioworks7, the latest expansion of its biological engineering foundry. With this new space, Ginkgo’s increased capacity will serve partners in cell and gene therapy, biomanufacturing and general mammalian programming for therapeutic applications and new biopharmaceutical… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this latest episode, DDW’s Megan Thomas is in conversation with two experts… Read More
